[{"data":1,"prerenderedAt":189},["ShallowReactive",2],{"drug-niacin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":23,"regimens":46,"contraindications":73,"warnings":83,"renal":91,"monitoring":92,"interactions":93,"review":94,"examples":97,"atc":103,"iran":105,"links":129,"populations":148,"usApproval":184},"niacin",1,{"fa":7,"en":8},"نیاسین (آهسته‌رهش)","Niacin (extended-release)","cardiovascular",{"fa":11,"en":12},"کاهنده چربی خون (اسید نیکوتینیک)","Lipid-modifying agent (nicotinic acid)",[14],{"name":15,"market":16},"Niaspan","US",[18,19,20,21,22],"niaspan","نیاسپان","nicotinic acid","اسید نیکوتینیک","نیاسین",[24,38],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":33,"refs":34},"er-500","tablet","oral","500 mg ER tablet (do not break)",{"amount":30,"unit":31,"perUnit":26,"scored":32},500,"mg",false,[16],[35],{"source":36,"section":37},"fda-niacin-er","3",{"id":39,"form":26,"route":27,"label":40,"concentration":41,"markets":43,"refs":44},"er-1000","1000 mg ER tablet (do not break)",{"amount":42,"unit":31,"perUnit":26,"scored":32},1000,[16],[45],{"source":36,"section":37},[47],{"id":48,"disease":49,"label":50,"population":53,"type":57,"unit":31,"dose":58,"refs":60,"notes":65},"lip","hyperlipidemia",{"fa":51,"en":52},"دیس‌لیپیدمی — شروع ۵۰۰ mg هنگام خواب؛ نگهدارنده ۱۰۰۰ تا ۲۰۰۰ mg یک بار","Dyslipidaemia — start 500 mg at bedtime; maintenance 1000–2000 mg once daily",{"minAge":54},{"value":55,"unit":56},18,"year","fixed",{"perDose":30,"perDoseMax":59,"dosesPerDay":5},2000,[61,63],{"source":36,"section":62},"2.1",{"source":36,"section":64},"2.2",[66],{"text":67,"refs":70},{"fa":68,"en":69},"با میان‌وعده کم‌چرب هنگام خواب. در هر ۴ هفته بیش از ۵۰۰ mg افزایش نه. بیش از ۲۰۰۰ mg\u002Fروز توصیه نمی‌شود.","At bedtime after a low-fat snack. Do not increase by more than 500 mg in any 4 weeks. Above 2000 mg\u002Fday not recommended.",[71,72],{"source":36,"section":62},{"source":36,"section":64},[74],{"id":75,"severity":76,"text":77,"refs":80},"ci","block",{"fa":78,"en":79},"بیماری فعال کبد یا افزایش بی‌علت ترانس‌آمینازها؛ زخم پپتیک فعال؛ خونریزی شریانی؛ حساسیت.","Active liver disease or unexplained transaminase elevation; active peptic ulcer; arterial bleeding; hypersensitivity.",[81],{"source":36,"section":82},"4",[84],{"text":85,"refs":88},{"fa":86,"en":87},"بدون کاهش رویداد قلبی؛ میوپاتی (به‌ویژه با استاتین)؛ آسیب کبد؛ افزایش قند و اسید اوریک؛ گرگرفتگی.","No reduction in cardiovascular events; myopathy (especially with statins); liver injury; raised glucose and uric acid; flushing.",[89],{"source":36,"section":90},"5",[],[],[],{"status":95,"reviewer":96,"date":96},"unverified",null,[98],{"regimen":48,"formulation":25,"input":99,"expect":102},{"ageYears":100,"weightKg":101},55,80,{"perDose":30,"tabletsPerDoseRounded":5,"upperPerDose":59},[104],"C10AD02",{"status":106,"forms":107,"refs":124},"registered",[108,112,116,120],{"code":109,"en":110,"fa":111},"09226","NICOTINIC ACID 1000MG TAB","قرص نیکوتینیک اسید ۱۰۰۰ میلی‌گرم",{"code":113,"en":114,"fa":115},"00898","NICOTINIC ACID 100MG TAB","قرص نیکوتینیک اسید ۱۰۰ میلی‌گرم",{"code":117,"en":118,"fa":119},"00899","NICOTINIC ACID 25MG TAB","قرص نیکوتینیک اسید ۲۵ میلی‌گرم",{"code":121,"en":122,"fa":123},"00900","NICOTINIC ACID 500MG TAB","قرص نیکوتینیک اسید ۵۰۰ میلی‌گرم",[125],{"source":126,"section":127,"url":128},"darooyab-generic","G-2915\u002FNicotinic-Acid","https:\u002F\u002Fwww.darooyab.ir\u002FG-2915\u002FNicotinic-Acid",[130,134,138,142,145],{"kind":131,"url":132,"label":133},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=203578","ANDA203578",{"kind":135,"url":136,"label":137},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6e604319-e164-4056-ab80-b78b98c519c7","FDA Niacin ER",{"kind":139,"url":140,"label":141},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682518.html","Niacin",{"kind":143,"url":144,"label":104},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C10AD02",{"kind":146,"url":128,"label":147},"darooyab","Nicotinic-Acid",{"pregnancy":149,"lactation":158,"pediatric":166,"geriatric":175},{"level":150,"text":151,"quote":154,"refs":155},"avoid",{"fa":152,"en":153},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Discontinue niacin extended-release when pregnancy is recognized in patients receiving the drug for the treatment of hyperlipidemia.",[156],{"source":36,"section":157},"8.1",{"level":150,"text":159,"quote":162,"refs":163},{"fa":160,"en":161},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfeeding infants, including hepatotoxicity, advise patients not to breastfeed during treatment with niacin extended-release.",[164],{"source":36,"section":165},"8.2",{"level":167,"text":168,"quote":171,"refs":172},"not-established",{"fa":169,"en":170},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of niacin therapy in pediatric patients (≤ 16 years) have not been established.",[173],{"source":36,"section":174},"8.4",{"level":176,"text":177,"quote":180,"refs":181},"caution",{"fa":178,"en":179},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of 979 patients in clinical studies of niacin extended-release, 21% of the patients were age 65 and over.",[182],{"source":36,"section":183},"8.5",{"kind":185,"refs":186,"id":133},"ANDA",[187],{"source":36,"section":188},"SPL approval \u002F marketing category",1792444703897]